Atlas Trials

A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies

Clinical trial NCT05780034 · RECRUITING

Trial details

NCT number
NCT05780034
Sponsor
Accutar Biotechnology Inc
Status
RECRUITING
Phase
Phase 1
Study type
INTERVENTIONAL
Relapsed/Refractory B-cell Malignancies
Start date
2023-06-20
Primary completion
2026-03-31
Enrollment
60

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.